Apr 13, 2023 · The AURORA (A Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH) study was a phase III, randomized, double-blind, placebo-controlled, 2 …

AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With …

PRIMARY Part 1: Percentage of Participants With Improvement in Fibrosis by at Least 1 Stage and No Worsening of Steatohepatitis on Liver Histology at Month 12 Fibrosis stage was evaluated using the …

Herein, we report efficacy and safety results from the phase III study. METHODS: AURORA was a phase III, randomized, double-blind, placebo-controlled, two-part study of patients with NASH and …

Primary efficacy endpoints will include the proportion of subjects with ≥1-stage improvement in liver fibrosis and no worsening of steatohepatitis at Month 12 relative to screening (Part 1), and time to …

Jan 13, 2017 · The AURORA study will be conducted in 2 parts. Part 1 will examine the surrogate endpoint of improvement in fibrosis of at least 1 stage (nonalcoholic steatohepatitis clinical research …

About this study The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult subjects with NASH. Participation eligibility …

Background And Aims: Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic …

RESULTS: The primary endpoint of improvement in fibrosis by ≥1 stage (NASH Clinical Research Network) AND no worsening of NASH (lobular inflammation or hepatocellular ballooning) on liver …

Research summary This is a Phase 3, multicenter, randomised, double-blind, placebo controlled study of Cenicriviroc Mesylate (CVC) for the treatment of Stage 2 to 3 liver fibrosis in adult participants with …